Platelets are small circulating anucleate cells that comprise the main component of particulate hemostasis (1) . Their key role in stopping bleeding means that low numbers or platelet dysfunction increases the risk of bleeding. Conversely, accentuated platelet function, as occurs in the presence of vascular risk factors such as hypertension and hyperlipidemia, contributes to acute coronary syndromes and stent thrombosis. As a result, antiplatelet agents such as aspirin and clopidogrel are used widely to reduce the risk of recurrent vascular events (2) (3) (4) .
In view of the relationship between reduced or accentuated platelet function and subsequent disease and clinical events, multiple approaches have been developed to assess platelet function. Extremely low number of platelets (thrombocytopenia, as occurs in terminal leukemia) or high numbers (thrombocythemia, a myeloproliferative disorder) are easily detected using automated hematology cell counters. Physiologically, platelet size and count are inversely related, and size can be measured using the same cell counters. Small low-function platelets are seen in terminal marrow failure, and large platelets are present and prognostic after acute myocardial infarction and ischemic stroke (5, 6) . However, these assessments of physical platelet parameters are indirect measures of function, and direct assessments have been developed. Historically, measurement of aggregation in plateletrich plasma predominated in research studies. This was not ideal in that the approach is time consuming, needs significant technical support, and measurements must be made near to the patient and within a few hours of blood collection.
Over the last 15 years, semi-automated "bedside" commercial tests have been developed that reduce time and operator dependence. Notable devices include Multiplate, VerifyNow, and Biocytex VASP (7) (8) (9) and these assays are promoted in an international consensus for platelet function testing in patients on dual antiplatelet therapy (10) . Nevertheless, the cost of these devices and their cartridges is relatively high, concordance between their results is not high (7, 11) , and measurements must be made near to the patient and within a few hours of venepuncture. Hence, the addition of a diagnostic requiring no capital investment that involves local blood sampling but with the flexibility provided by remote measurement is potentially a welcome addition to the armamentarium of measuring platelet function.
P-selectin
P-selectin (CD62P) is a protein that functions as a cell adhesion molecule on the surface of activated platelets and endothelial cells. In both cell types, P-selectin is stored in alpha-granules and is translocated to the cell surface following cell activation. In platelets, activation is driven by stimulation by vascular agonists such as thrombin, collagen, adenosine diphosphate (ADP), thromboxane A 2 , and its mimetics and inflammatory agonists including interleukin-4. The relationship between circulating soluble P-selectin and vascular diagnoses and outcomes is well described, for example, in stroke (12), and reflects both platelet and endothelial function. In contrast, measurement of P-selectin on the platelet surface assesses the extent of platelet activation and expression changes in response to the same agonist(s) that cause platelets to aggregate together. One role for P-selectin on activated platelets is that it binds to a specific receptor, P-selectin glycoprotein ligand-1, which is expressed on most leucocytes (neutrophils, monocytes, lymphocytes, eosinophils), thus facilitating platelet-leucocyte conjugation.
Remote assessment of platelet function with P-selectin Measurement of the surface expression on platelets of P-selectin provides an alternative approach to assessing platelet function and standardized tests are now available for a number of different purposes (Platelet Solutions Ltd., PSL). Blood is taken by conventional venepuncture, placed in warmed reaction tubes (13) , stimulated with selected agonist(s) (which leads to expression of P-selectin onto the surface of platelets), fixed with PAMFix (14), posted to a core laboratory, and surface P-selectin measured using flow cytometry (15) . One agonist is arachidonic acid (AA), the effects of which are blocked by aspirin (aspirin test). The clopidogrel test detects whether P2Y 12 antagonists such as clopidogrel, prasugrel, and ticagrelor prevent ADP stimulation of platelets. By comparing data obtained using a number of different agonists, information on the presence of platelet dysfunction or inhibition in an individual can be obtained. Fixation prevents both platelet aggregation and platelet-leucocyte conjugate formation so that all activated single platelets are available for analysis.
In a comparison with light transmission aggregometry, Multiplate, VerifyNow, and Biocytex VASP, the P-selectinbased aspirin and clopidogrel tests were at least as effective in determining the inhibitory effects of antiplatelet therapies including combined aspirin and clopidogrel, and combined aspirin and prasugrel (16) . But what does differentiate assessment of platelet expression of P-selectin from these other tests is that samples may be sent by post from where the patient is (hospital, general practice, home) to a core laboratory for measurement, results can then be returned the next day. The test is stable for at least 28 days (9) (and possibly 35 days (17)) allowing between-country as well within-country measurements. This approach is similar to the measurement of other vascular risk factors such as blood cholesterol.
Measurement of platelet expression of P-selectin may be combined with other platelet assessments. For example, P-selectin and CD63 (a marker of dense body secretion) may be assessed on activated platelets in patients with enhanced bruising to diagnose mild bleeding disorders (18) .
Resistance
Although antiplatelet agents are highly effective at reducing the risk of recurrent vascular events, a significant minority of patients (≥35%) do not respond adequately to clopidogrel (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) , a similar but lesser problem also exists for aspirin (8, 19, 21, 23, 29) . High residual platelet reactivity whilst on treatment (HRPR, amounting to resistance or nonresponse) can follow failure to take or absorb the tablets, or to convert the drug into its active metabolite, or for the metabolite to inhibit platelet function, i.e., a mix of patient, drug, and genetic-related factors. It is widely assumed that nonresponse means that antiplatelet therapy will have only a limited effect on reducing vascular events (antiplatelet failure); hence, patients with HRPR are in essence taking an ineffective medication and so remain at increased risk of recurrent events. Evidence for this comes from a substudy of the clopidogrel in high-risk patients with Acute Non-disabling Cerebrovascular Events trial that showed that the combination of aspirin and clopidogrel was superior to aspirin alone in preventing recurrence after minor ischemic stroke or TIA. However, the presence of the CYP2C19 loss-of-function allele was associated with a failure for clopidogrel to add to aspirin in preventing recurrence (30) . Around 14% of patients are CYP2C19-poor metabolizers. A key reason for testing platelet function is to identify patients who exhibit HRPR.
Proton pump inhibitors
Drug interactions are common with antiplatelet agents. Clopidogrel is a prodrug that requires activation by cytochrome P450 (especially CYP2C19) to form an active metabolite. Initially, there was concern that gastroprotection with proton pump inhibitors, which can inhibit CYP2C19, should be avoided. This advice was attenuated to suggesting that omeprazole and esomeprazole should be avoided. A recent meta-analysis found that the PPI-clopidogrel interaction seen in vitro has no clinical significance (31) . Rather, patients taking PPIs are likely to have more comorbidities and therefore a higher vascular risk. As a result, there is no clinical role for monitoring platelet function when patients are taking clopidogrel and a PPI.
Clinical studies

Volunteers
Several studies have been reported in normal volunteers as part of the development of the aspirin and clopidogrel P-selectin tests (15, 32) . These show the utility of the aspirin test for assessing aspirin with suppression of AA-stimulated P-selectin expression. Similar findings have been made for the clopidogrel test for ADPstimulated P-selectin.
Myocardial infarction
Platelets are activated in acute myocardial infarction and chronically afterward and in procedures such as angioplasty and stent insertion. Antiplatelet agents such as aspirin, clopidogrel, and prasugrel are effective in reducing the risk of recurrent events (3, 4) . In a study of 100 patients with acute coronary syndrome and who were on combined aspirin and clopidogrel, the clopidogrel test found that a majority of patients had a high on-treatment platelet reactivity (Table I) (33) . In patients who went on to develop a further cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or stent thrombosis) during the following 12 months, the P-selectin levels were higher than in patients who had no further event. All patients had a suppressed aspirin test and there was no difference in aspirin-related P-selectin expression between patients who developed, or did not develop, a subsequent cardiovascular event (Table I) (33) .
In a further study of patients with recent ACS (34), ADPstimulated P-selectin expression (clopidogrel test) was measured 1 month after starting clopidogrel or prasugrel. HRPR was higher in those taking clopidogrel than those on prasugrel (Table I) . However, P-selectin levels were higher in prasugrel users if they had hypertension than if they did not.
A comparison of clopidogrel and prasugrel was made in another study of patients with ACS (9) . Prasugrel treatment resulted in significantly greater inhibition than clopidogrel. Three patients with very high P-selectin values were subsequently found to be not taking prasugrel. Additionally, three patients had high AA-stimulated high P-selectin expression and were either nonresponders to aspirin or more likely not taking this drug (9) .
Stroke
Platelets are activated in acute stroke and chronically afterward, and antiplatelet agents such as aspirin, clopidogrel, and dipyridamole are effective in reducing the risk of recurrence (4, 35, 36) . The effect of aspirin and clopidogrel on platelet expression of P-selectin was assessed in the large Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial; TARDIS compared the effect of intensive (combined aspirin, clopidogrel, and dipyridamole) versus guideline (combined aspirin and dipyridamole, or clopidogrel alone) in patients with acute stroke or transient ischemic attack (37, 38) . At baseline, the aspirin test identified patients who declared that they had been taking this antiplatelet before randomization; HRPR was present with aspirin in only 4.7% of patients (Table I) (39, 40) . Whilst the clopidogrel test similarly identified patients saying that they had been taking this drug, 24.7% of them did not have suppressed platelet expression of P-selectin (39, 40) . For so-far unexplained reasons, the presence of a second antiplatelet was associated with higher P-selectin expression than if only one antiplatelet, e.g., AA-stimulated P-selectin (aspirin test) was higher in patients taking combined aspirin and clopidogrel than aspirin alone (Table I ). The effects of randomized treatment on P-selectin expression and relationship between P-selectin levels and subsequent stroke recurrence and bleeding are to be analyzed.
In the Pre-Accrist study, 62 patients with recent stroke and who were taking clopidogrel were studied; minority were also taking aspirin. Twenty-three percent of patients did not have suppressed levels for the clopidogrel test (41) . At one neuroscience center, the clopidogrel test is being used off-label to identify nonresponse to clopidogrel in patients having coiling of cerebral aneurysms (42) , such patients are changed to prasugrel prior to the procedure if they appear to have HRPR on this P2Y 12 antagonist (Table I ). The use of the test is exemplified in one patient who had unsuppressed P-selectin expression on the aspirin test, the test suppressed when the patient became compliant of medication.
Surgery
Many older patients take aspirin regularly for vascular (or cancer) prophylaxis. The question then arises as to whether this should be stopped temporarily before major surgery to prevent the perceived risk of increased operative blood loss. In an observational study, the effect of stopping aspirin preoperatively in 20 patients having colorectal surgery was assessed and compared with a group who were not on aspirin (43) . P-selectin expression was lower on aspirin (Table I ) and within 5 days of stopping aspirin prior to surgery. The aspirin test showed that P-selectin expression rose with the length of time between stopping aspirin and surgery. Although the proportion of patients with a complication, including those with hemorrhage, was higher in the aspirin group, P-selectin expression was not associated with complications or bleeding (43) .
Veterinary medicine
One study assessed whether P-selectin expression could be used to measure platelet function in dogs (44) . The relevance is that pets are increasingly given antiplatelet drugs to prevent vascular disease. Using antibodies against canine P-selectin, it was possible to measure platelet function and the inhibitory effects of antiplatelet agents (Table I) . A study is ongoing in cats.
Bleeding disorders
The above clinical disorders all share the use of P-selectin to assess the inhibitory effects of antiplatelet agents. However, P-selectin expression may also be used to diagnose mild bleeding disorders (45) such as defects in dense granule secretion, thromboxane A 2 pathway, GI signaling, response to collagen, or response to thrombin receptor activating peptide (18) . The results were comparable to light transmission aggregometry/lumiaggregometry (Table I) , a time-and labor-intensive technique that has to be performed shortly after venepuncture.
Clinical P-selectin measurements
The table summarizes results from clinical studies in normal volunteers, patients with vascular or hematological disorders or those having surgery, and in dogs. Whilst comparisons between studies are difficult using summary data, the following observations may be made.
The clopidogrel test is sensitive to the presence of ADP receptor antagonists such as clopidogrel and prasugrel. Typically, volunteers or patients who are not on an antagonist exhibit values above 800 units whilst those on clopidogrel have expression levels below 700 units. Limited data suggest that prasugrel lowers expression more than clopidogrel. Using a predefined cutoff of 860 units (33), a significant proportion of patients on clopidogrel do not suppress (i.e., high platelet reactivity whilst on treatment), this ranging between 6% and 36% (with one study finding it as high as 58% (33)).
The aspirin test showed that individuals who were taking this inhibitor of cyclooxygenase typically had P-selectin expression below 500 units (and often <200 units) whilst those not taking aspirin usually exceeded 500 units (and often >900 units). High platelet reactivity (using a cutoff of >500 units) was uncommon on aspirin, typically affecting <5% individuals.
Future prospects
Use of remote P-selectin measurement offers great promise but several important questions remain. First, P-selectin expression varies considerably between individuals and a key question is what values should be used for deciding that a patient has high platelet reactivity if on an antiplatelet or a low value in the presence of bleeding. Typically, cut-points need to be defined by outcome data so that patients with a value on one side of the cut-point are much more likely to have an event than if on the other side. Practically, this means defining the cut-point using one set of data and then testing it using a second data source. To date, the only cut-point to be defined in this way is the value of >860 units for the clopidogrel test which signals high platelet reactivity on clopidogrel (33) .
Second, predictors of high platelet reactivity on clopidogrel need to be identified. It is likely that high platelet reactivity on treatment will be associated with increasing age, male sex, presence of vascular risk factors such as hypertension and diabetes mellitus, and having an acute vascular event. Although a study of patients with acute coronary syndrome found no such difference (33) , it was small and the comparisons were probably underpowered statistically.
Third, the relationship between P-selectin expression and outcome needs to be further defined. For example, it can be hypothesized that patients with suppressed P-selectin expression will be less likely to suffer a vascular event when taking antiplatelet therapy than those whose level is not suppressed. This scenario was seen in the small study in acute coronary syndrome, whereby those on clopidogrel who went on to develop a further cardiovascular event had higher platelet P-selectin expression than those who had no further event (33) . Equally, increased bleeding might be associated with very suppressed P-selectin expression. This is being studied in a larger sample of patients with recent acute ischemic stroke or TIA who were recruited into the TARDIS trial. Nevertheless, the relationship between assessment of platelet function and subsequent vascular events is challenging to assess and previous studies using other platelet function assessments have found poor correlation between platelet function testing and subsequent events (46) .
If high platelet reactivity is related to outcomes, then a fifth question is whether changing treatment reduces not just platelet function but more importantly vascular events. Hence, patients with recent cerebral ischemia and apparent resistance to clopidogrel might best be changed to an alternative antiplatelet regimen such as combined aspirin and clopidogrel. Trials addressing this type of question have yet to be reported.
Sixth, the concept of de-escalation has been reported recently whereby patients taking an expensive antiplatelet agent such as ticagrelor or prasugrel are switched to clopidogrel for reasons of cost or bleeding. It is then necessary to assess whether HRPR is present in which case treatment would be reescalated to the original antiplatelet. The TROPICAL-ACS study used this approach with platelet function assessed using Multiplate (47) . The P-selectin approach offers a potential alternative diagnostic for de-escalation and needs further study.
A seventh area for future research is to expand the indication for testing platelet function. The majority of studies quoted here have focused on vascular diseases (9,33,34,39,40) or diagnosis of bleeding (18) . Other potential indications include assessment of risk of bleeding prior to surgery, confirmation that platelet function is appropriately attenuated prior to invasive procedures, and veterinary uses. However, the use of P-selectin measurement for managing other diseases where platelets may contribute to pathogenic processes remains untested, with examples including cancer, dementia, and valvular heart disease (48, 49) . Similarly, pharmaceutical development may need to demonstrate that novel agents do, or do not, have antiplatelet effects.
Finally, the studies quoted here involved a single core laboratory in Nottingham for flow cytometric quantification of P-selectin expression on the surface of platelets. Flow cytometers are widely available and there is no reason why other laboratories should not perform these assessments, although quality control systems would need to be set-up to ensure that results were comparable between laboratories, as we did previously for international assessment of mean platelet volume (6) .
